Neonates requiring a Prostaglandin Infusion v4.1
Preview
Overview
The Trust Guideline is to ensure that neonates who have been prescribed a prostaglandin dinoprostone alprostadil or epoprostenol by medical staff are cared for in a safe and appropriate manner.
Categories
ClinicalReference
Date Uploaded
27.04.2020Date Review
27.04.2023File Size
82KbClinical Guidelines
This guideline has been approved by the Trust's Clinical Guidelines Assessment Panel as an aid to the diagnosis and management of relevant patients and clinical circumstances. Not every patient or situation fits neatly into a standard guideline scenario and the guideline must be interpreted and applied in practice in the light of prevailing clinical circumstances, the diagnostic and treatment options available and the professional judgement, knowledge and expertise of relevant clinicians. It is advised that the rationale for any departure from relevant guidance should be documented in the patient's case notes.The Trust's guidelines are made publicly available as part of the collective endeavour to continuously improve the quality of healthcare through sharing medical experience and knowledge. The Trust accepts no responsibility for any misunderstanding or misapplication of this document.